文献速递头颈部肿瘤放疗

剂量递增立体定向放射外科加量治疗不良预后局部晚期口咽癌的I期试验

Phase I trial of dose-escalated stereotactic radiosurgery (SRS) boost for unfavorable locally advanced oropharyngeal cancer.
PubMed 文献 · Radiat Oncol · 2020-12-11

这项前瞻性I期试验纳入34例中危或高危口咽鳞状细胞癌患者,在同步顺铂和60 Gy或66 Gy分次放疗后,对残留大体肿瘤行立体定向放射外科加量(单次8 Gy、单次10 Gy或两次5 Gy)。主要终点为治疗毒性,中位随访4.2年时局部、区域和远处控制率分别为85.3%、85.3%和88.2%,总生存率85.3%,未发生治疗相关5级毒性。

要点

  • 34例中高危口咽鳞癌患者接受同步放化疗后SRS加量,主要终点为毒性。
  • 4例出现肿瘤坏死致3级吞咽困难,其中3例发生需手术干预的4级咽部出血。
  • 中位随访4.2年局部、区域、远处控制率均为85%左右,总生存率85.3%。

核心结论

  • SRS加量剂量递增在中危或高危口咽鳞癌中可行,但需更长随访和更大样本验证后方可常规临床实施。

研究设计与样本

  • 前瞻性I期试验,2010-2017年纳入34例中危或高危口咽鳞状细胞癌患者。
  • 患者接受同步顺铂和分次放疗总剂量60 Gy或66 Gy,随后对残留大体肿瘤行SRS加量。
  • SRS加量方案为单次8 Gy、单次10 Gy或两次5 Gy,主要终点为治疗毒性。

主要发现

  • 急性毒性包括4例肿瘤坏死导致3级吞咽困难,其中3例发生需手术干预的4级咽部出血。
  • 治疗后24个月,2级味觉障碍、口干和吞咽困难发生率分别为7%、9%和15%,2例仍依赖喂养管。
  • 未发生继发于治疗的5级毒性。
  • 中位随访4.2年时局部、区域和远处控制率分别为85.3%、85.3%和88.2%,5例死亡,总生存率85.3%。

关键数值与推荐

  • 分次放疗总剂量为60 Gy或66 Gy。
  • SRS加量方案为单次8 Gy、单次10 Gy或两次5 Gy。
  • 中位随访4.2年时局部控制率85.3%、区域控制率85.3%、远处控制率88.2%、总生存率85.3%。

临床怎么用

  • 该SRS加量策略目前仍属研究性,需更长随访、更大队列和加量方法优化后再考虑常规临床应用。

局限性

  • 样本量小(34例),随访时间有限,加量方法需进一步优化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Patients with locally advanced oropharynx squamous cell carcinoma have suboptimal outcomes with standard chemoradiation. Here, we evaluated toxicity and oncologic outcomes of dose escalation using radiosurgical boost for patients with unfavorable oropharynx squamous cell carcinoma. MATERIALS AND METHODS: Between 2010-2017, Thirty four patients with intermediate- or high-risk oropharynx squamous cell carcinoma were enrolled onto this prospective phase I trial. Each patient received concurrent cisplatin and fractionated radiotherapy totaling 60 Gy or 66 Gy followed by radiosurgery boost to areas of residual gross tumor: single fraction of 8 Gy or 10 Gy, or two fractions of 5 Gy each. Primary endpoint was treatment toxicity. Secondary endpoints were local, regional, and distant disease control. RESULTS: Eleven, sixteen and seven patients received radiosurgery boost with 8 Gy in 1 fraction, 10 Gy in 1 fraction, and 10 Gy in 2 fractions respectively. Acute toxicities include 4 patients with tumor necrosis causing grade 3 dysphagia, of which 3 developed grade 4 pharyngeal hemorrhage requiring surgical intervention. At 24 months after treatment, 7%, 9%, and 15% had grade 2 dysgeusia, xerostomia, and dysphagia, respectively, and two patients remained feeding tube dependent. No grade 5 toxicities occurred secondary to treatment. Local, regional, and distant control at a median follow up of 4.2 years were 85.3%, 85.3% and 88.2%, respectively. Five patients died resulting in overall survival of 85.3%. CONCLUSIONS: This study is the first to report the use of radiosurgery boost dose escalation in patients with unfavorable oropharynx squamous cell carcinoma. Longer follow-up, larger cohorts, and further refinement of boost methodology are needed prior to implementation in routine clinical practice. TRIAL REGISTRATION: Northwell Health Protocol #09-309A (NCT02703493) ( https://clinicaltrials.gov/ct2/show/NCT02703493 ).

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Vempati P, Halthore AN, Teckie S, et al. Phase I trial of dose-escalated stereotactic radiosurgery (SRS) boost for unfavorable locally advanced oropharyngeal cancer. Radiat Oncol. 2020. PMID: 33308265. doi:10.1186/s13014-020-01718-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。